cannabinoida and cancer and how it works

[duke]

cannabinoids and cancer how does it work? eta (i in no way am saying cannabis "cures" cancer but can help sometimes)
hi all i found this article very good and mostly easy to understand,thats the trouble its all well and good finding research and stuff but unless one has a biology degree much of it is uninteligable so i like this one,peace and enjoy,

Cannabinoids display “antitumor properties such as inhibition of cancer cell growth, induction of apoptosis and blocking the processes involved in tumor progression, such as angiogenesis, and cell migration. These effects might involve several signaling pathways being both cannabinoid receptor dependent or independent” (Pisanti 2009).

When a person reads the above quote they may feel it's the end of the story. Cannabis kills cancer. But is that really where the story ends? Pro-cannabis researchers and pro-cannabis activists seem to have differing opinions on the answer. Many activists are promoting cannabis that's high in THC for any and all types of tumors. Researchers suggest that THC appears to have a great deal of potential in the treatment of a large number of cancer cell lines, but that it's not always the best cannabinoid to choose for a cancer based treatment. Why is that?

– The Expression Level of Cannabinoids Receptors

The level of expression (the number of) of cannabinoid receptors (CBRs) in tumor cells appears to be a fundamental factor to the overall effectiveness of cannabinoid based cancer treatments. Most cannabinoids are CBR activators. These receptors are 'doing all the work' so to speak. It is not the cannabis or cannabinoids themselves that have anticancer properties, it is the cannabinoids ability to latch onto and activate the appropriate receptors. The activation of these receptors unleashes a cascade of events and mechanisms, some of which are advantages in slowing the progression and inducing apoptosis in tumor cells. CBR activation is fundamental to all cannabinoid based treatments. If this sounds relatively straight forward, that's because in a way it is. In order for cannabinoids to elicit any anticancer effects they must be able to activate the specific CBRs in the tumor cells. The higher the expression level of receptors, the greater impact that cannabinoids that activate those receptors have in the treatment. If there are no receptors to activate in the target area, or the cannabinoids being used are more effective at activating a different receptor, the treatment is likely to be relatively unsuccessful. (Pisanti 2009)

Equally vital is the awareness that tumor cells with low or undetectable expression levels of CBRs are resistant to any anticancer effects that cannabinoids may elicit, and the immunosuppression resulting from the systemic application of cannabinoids have been shown to enhance tumor growth in some cancer cell lines (like some types of breast cancer). (Pisanti 2009)

This paper will attempt to point to some of the research in relation to cancer, the endocannabinoid system (ECS), and natural cannabinoids that activate it. It may surprise some readers to learn that there is a growing number of legal and natural cannabinoids which originate outside of the cannabis plant. Many of these are cheap, highly available, and share a number of anticancer characteristics to cannabinoids in cannabis via the activation of similar receptors.

– Receptors/Targets to Consider in Cancer Treatments

The primary targets or mechanisms of action in cannabinoid based cancer treatments involve the
activation of CB1 and CB2 receptors. It seems likely that one reason THC has proven to be relatively
effective (particularly when combined with other cannabinoids) is based on the fact that it's a CB1 and
CB2 activator. However, THC activates CB1 much more efficiently than CB2, which is why other
cannabinoids might be better options for treatments that would benefit from CB2 activation.

In addition to the activation of CB1 and CB2, some cannabinoids also activate TRPV1 which has been shown to induce apoptosis in tumor cells. Another target worthy of mention is GPR55. Unlike the other receptors which we are attempting to activate in cancer treatments, GPR55 activation by natural compounds in the body (as well as exogenous sources) actually leads to the proliferation of tumor cells, so it is beneficial to block GPR55 rather than activate it. Luckily enough there are cannabinoids that block GPR55. Both CBD and magnolia officinalis extracts block the activation of GPR55 and slow the proliferation of tumor cells. (Pisanti 2009)

– Partial List of Potentially Useful Cannabinoids in Cancer Treatments

List of cannabinoids with some of the relevant receptors that they target:

• THC – CB1/CB2 partial activator with CB1 selectivity (more potent CB1 activator), TRPV1 activator
• CBN – CB1/CB2 partial activator with CB1 selectivity (weaker than THC)
• CBG – CB2 activator, AEA reuptake inhibitor
• CBD – TRPV1 activator, GPR55 blocker, raises AEA and 2-AG levels, AEA reuptake inhibitor
• CBDA – TRPV1 activator




This is not a definitive list, but there might be a few cannabinoids listed that many patients aren't
familiar with.

The first two I'll point out are AEA and 2-AG. These are endocannabinoids (natural cannabinoids in the human body). These are listed for a few select reasons. They are CBR activators with anticancer characteristics that are naturally produced by the body. That knowledge on its own might not mean much, but coupled with the knowledge of inexpensive ways of increasing endocannabinoid levels it can be quite useful information. Dietary linoleic acid has been shown to raise levels of both AEA and 2-AG. This is an inexpensive way to increase the body's own natural cannabinoids. CBD also raises levels of both AEA and 2-AG via FAAH inhibition. In addition, CBD, CBG, and CBC are all AEA reuptake inhibitors (which raise AEA levels).

Next is beta-caryophyllene. Beta-caryophyllene is of value in that it is a full CB2 activator that is naturally found in a number of dietary sources. It can also be found in concentrated levels in a variety of essential oils and nutritional supplements. In some treatments (like some types of breast cancer) CB2 activation is likely of greater importance than CB1.

One of the most highly researched in regards to anticancer potential is the magnolia officinalis.
Magnolia officinalis root bark has been used in Chinese medicine for 2000 years. It contains magnolol
and honokiol which are both cannabinoids with anticancer characteristics. They activate CB1, CB2, and also block GPR55. A point worth mentioning is that they are both known to target apoptosis, which
might make their addition to any cannabis based (specifically THC) treatment potentially beneficial.

The final two are echinacea purpurea (CB2 activator) and kava-kava (CB1 activator). These are
both relatively new discoveries and there isn't much information about their specific characteristics in
regards to cancer treatment, but as CB1 and CB2 are both targets, it might be safe to assume that these have potential as well.

– Targets/Receptors and Cannabinoids to Consider for Specific Types of Cancer

So now that we are familiar with our targets (receptors) and our weapons (cannabinoids) let's see how this all relates to some types of cancer:

Breast Cancer

• CB1 expression level is lowered
• CB2 expression level rises
• AEA and 2-AG via CB1 activation reduces cell proliferation
• THC immunosupression and non CBR mechanisms have been shown to increase tumor growth
and metastisis in some cell lines.
• THC induces apoptosis via CB2 activation (better options for CB2 activation)
• CBD inhibition and apoptosis via CB2 and TRPV1
• Magnolia officinalis cannabinoids have a great deal of positive research in this treatment
• THC might not be the most appropriate cannabinoid for all types of breast cancer. (Reader is advised to review research on individual cancer cell lines in relation to this topic in the provided citations.)

Prostate Cancer

• CB1 and CB2 expression levels rise
• TRPV1 expression levels rise
• AEA via CB1 and CB2 inhibits proliferation
• THC induces apoptosis via non CBR
• Other cannabinoids have been shown to induce apoptosis via CB1 and CB2
• Magnolia officinalis cannabinoids have a great deal of positive research in this treatment
• Many cannabinoids might be well suited

Skin cancer

• No information on changes of expression levels, but CB2 is highly expressed in the skin
• Cannabinoids have been shown to inhibit growth via CB1 and CB2 activation
• Beta-caryophyllene from essential oils can be used in topical applications
• Magnolia officinalis cannabinoids have a great deal of positive research in this treatment

Pancreatic Cancer

• CB1 and CB2 expression levels rise
• THC induces apoptosis via CB2 and ceramide
• Magnolia officinalis cannabinoids have a great deal of positive research in this treatment


– How Treatment Schedule Might Effect the Efficacy of Treatments

It also seems important to stress the potential relevance of treatment schedules. This is a point that directly relates to the expression level of CBRs, which we now understand the role of. The average lifespan of a cannabinoid receptor is around 0.5 seconds. Their level of expression is constantly in flux. Patients who have consumed cannabis for extended periods of time are familiar with the fact that a "tolerance" is quickly established to cannabinoids. The same is true for patients during cancer treatments. This is in large part due to the level of cannabinoid receptors being lowered and becoming fatigued by the constant exposure to exogenous cannabinoids. It is also commonly accepted among those who consume cannabis daily that abstaining from cannabis for 24-48hrs lowers a person's tolerance and increases the effects elicited by cannabinoids.